Regentis Biomaterials (RGNT) Debt Ratio (2024 - 2025)
Regentis Biomaterials' (RGNT) quarterly Debt Ratio came in at 0.31 in Q4 2025, down 96.94% year-over-year from 10.26 in Q4 2024, and down 96.94% quarter-over-quarter from 10.26 in Q4 2024.
Powered by 
Analysis
Regentis Biomaterials (RGNT) Debt Ratio (2024 - 2025) Analysis & Trends
Regentis Biomaterials (RGNT) has reported Debt Ratio for 2 consecutive years, with 0.31 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Debt Ratio fell 96.94% year-over-year to 0.31 in Q4 2025; TTM through Dec 2025 was 0.31, a 96.94% decrease from a year earlier, with the FY2025 full-year figure at 0.31, down 96.94% from the prior year.
- Debt Ratio was 0.31 for Q4 2025 at Regentis Biomaterials, down from 10.26 in the prior quarter.
- Over five years, Debt Ratio peaked at 10.26 in Q4 2024 and troughed at 0.31 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 0.30 |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 0.30 |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 0.31 |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 0.28 |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 0.04 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 0.13 |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | - |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 0.20 |
| 10 | Regentis Biomaterials | 1.12 Mn | -6.26 Mn | - | 0.31 |